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ABSTRACT
Objective: To determine the pattern of anticoagulation control for post heart-valve surgery
for patients on follow up at Kenyatta National Hospital(KNH).
Design: A combined prospective and restrospective hospital-based study. Retrospective
period from January 1991 to 31st August 1997, while the prospective period was from 1st
September 1997 to 31st November 1999.
Setting: Cardiothoracic surgery clinic, Kenyatta National Hospital, Nairobi.
Patients: Post heart valve surgery patients on warfarin and attending the cardiothoracic
surgery clinic at Kenyatta National Hospital.
Main outcome measures: Clinic attendance intervals, average warfarin dosages, interval of
dosage change, INR values and variations from accepted normal.
Results: A total of 103 patients fulfilled the criteria for inclusion into the study consisting of
77 mitral valve replacements, 18 aortic valve replacements, seven double valve replacements
and one mitral valve repair. The total follow up time for the study period is 316.9 patients
years. On average, patients attended their anticoagulation clinic once every 59 days. The
average dose of warfarin prescribed was 6.81mg daily(±2.67mg), with double valve
replacement patients receiving a statistically significant lower dosage of 6.04 mg (±1.36mg),
(95% confidence limits). On average, a warfarin dose change was made 1.48 times a year per
patient. For all the patients, the mean INR was 2.50 (±1.18). The respective values for mitral,
aortic, double valve replacement and the mitral repairs were 2.53(±1.21), 2.32 (±1.04), 2.5
(±1.05) and 2.02 (±0.53), respectively. Mitral valve repair patients maintained a significantly
lower level of INR (95% confidence limits). Only during 18% of the follow up time was
adequate anticoagulation maintained. During the study period only 6.9% of patients were
able to maintain adequate anticoagulation for 50% or more of their follow up time.
Conclusion: Anticoagulation control at the KNH still needs some improvements in clinic
attendance and better dosage adjustments to achieve more appropriate INR values.
INTRODUCTION
Anticoagulation forms an essential part of the follow
up of all patients with prosthetic heart valves with or without
atrial fibrillation. The use of anticoagulation in this group of
patients is now well established and essential to reduce
morbidity associated with this state(1,2). The relative risk
varies with the different models of valves, (all of which have
different haemodynamic characteristics), patients age, left
atrial size, the presence of congestive cardiac failure and
atrial fibrillation amongst other things(3).
In order to prevent thrombo-embolic phenomena
anticoagulants are prescribed, of which warfarin is the
most common. Appropriate levels of anticoagulation using
warfarin are now universally monitored by the international
normalised ration (INR).
The WHO introduced INR as a mode of standardising
anticoagulation in the early 1980s(4) and this was
subsequently adopted at the Kenyatta National Hospital
(KNH), Nairobi in 1987. This standardisation became
necessary due to the widely differing anticoagulation
protocols and thromboplastins in place worldwide prior
the time. The year 1991 was the first full year from when
INR was used on a routine basis at the KNH.
The ideal level of anticoagulation in post-operative
valve patients has been subject of a lot of debate over the years
and was previously based on observational studies rather than
scientific testing(5,6). More recently the concept of valve
specific anticoagulation is emerging as it has been realised
that the thrombogenicity of different valves varies widely.
The newer (or second generation) range of valves are generally
less thrombogenic than their first generation counterparts.
Key to the efficient control anticoagulation is the
formation of a reliable follow up service of the patients.
Regular attendance by the patients, supplemented by  a
system of quality control anticaogulation are the
prerequisites of such a service. In some centres where such
quality control systems are in place, levels of adequate
INR control maintained up to 80% of the patients attending
the anticoagulation clinic for up to 60% or more their
follow up time(8).
This study looks at the pattern of anticoagulation
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control at the KNH, Nairobi. The target population was the
post heart valve surgery patients on anticoagulation
attending the cardiothoracic surgery clinic.
MATERIALS AND METHODS
The study was carried out as a combined prospective and
retrospective review of the pattern of clinic attendance and their
anticoagulation control during the period from January 1991 to
November 1999. Patient data were collected retrospectively from
the patient files and  anticoaguation control during the period from
January 1991  to  August 1997. Prospective data were obtained from
follow up of the patients from September 1997 to November 1999.
Data collected from the patient files and anticoagulation
booklets included details of the operative procedure, date of
hospital discharge, all clinic attendance dates, INR estimation
during each visit and warfarin dosage. Anticoagulation related
morbidity and mortality data were not collected as this was a
“preliminary data base” study. These details listed above were
only documented for patients on follow up over the period from
January 1991 onwards irrespective of the date of their surgery.
All data collected (prospective and retrospectively) were
amalgamated to make up a full data sheet for each patient.
All patient operated on at the KNH whose files could be
traced in the record’s office and those seen in the cardiothoracic
surgery clinic were considered for inclusion into the study. The
patients included in the study were those who had valve
replacements and open valve repair procedures and on warfarin
prophylaxis. Closed valvotomies and aortic ridge resections
were not included.
Excluded from the study were patients attending the
cardiothoracic clinic at KNH but had their first or subsequent
open-heart surgery performed outside the KNH. Also excluded
were those patients who either failed to attend postoperative
clinic follow ups or made less than two postoperative clinic
attendance post-discharge. The final group of patients excluded
were those who though they attended follow up, ceased to do so
prior to 1st January 1991, (the time from which INR estimation
was utilised on a routine basis at the KNH).
Data were analysed as mean, standard deviation, and
confidence limits, the latter illustrated by box and whisker charts.
Significance at a 95% level is taken as statistically significant.
The ranges of INR by the British Society of Haematologists
for assessment of anticoagulant control were adopted for this
study(9). These ranges are an INR level of less than two (or under
anticoagulated), between 2 and 2.5, 2.5 to 3.0, 3.0 to 4.5 (the
latter being the level previously recommended for all prosthetic
valves) and finally greater than 4.5 (or over anticoagulated).
Calculation of the durations in which the various of INR levels
were maintained by the patients was done using the method of
Duxbury, 1982(8). This method takes into account that not all
INR estimations are done with the same interval in between tests.
RESULTS
Over the study period, a total of 103 patients fulfilled
the criteria for inclusion into the study. There were 77
mitral valve patients, eighteen aortic patients, seven double
valve patients and one mitral valve repair.
For all patients included, a total of 1836 clinic contacts
were recorded making a total follow up period of 115,765
patient days(316.9 patient years). Out of these clinic visits, a
total of 1,770(96.4%), of them had INR results available. A
total of 13356 contacts (73.86%), had warfarin doses retrieved.
For all patients combined the average interval between
clinic visits at 58.95 days (±95.74 days). For the mitral
valve replacement patients the average interval between
clinic attendance is 57.06 days (± 88.68 days) for aortic
valve patients 58.22 days (± 71.42) and the double valve
replacement patients 76.24 days (± 172.5 days). There was
no statistically significant difference between the intervals
of clinic visits for the four groups.
All patients reviewed were on warfarin medication.
The mean dosage of warfarin prescribed for all the patients
was 6.81mg daily (± 2.67mg). The respective figures of the
patients with single mitral valve replacement, single aortic
valve replacement and double valve were 6.77mg (±2.8mg),
7.32mg(±2.17mg) and 6.04mg(±1.36mg). The double valve
replacement patients were receiving a statistically significant
lower dose of warfarin than the other valve groups (Figure
1). The mitral valve repair patient was on warfarin but the
dosage were inadvertently not recorded.
Figure 1
Mean warfarin dose prescribed per valve site
Figure 2
Mean INR for different valve sites
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Figure 3
INR control in range 3.0-4.5 for valve patients
During the study period a total of 468 changes in the
dosage of warfarin were made. The average number of
warfarin dosage changes for all patients made per year was
at 1.48 changes per patient per year .
For all INR values recorded the mean INR for all
patients was 2.50(±1.18) and the respective values for
mitral, aortic, double valve patients and open mitral valve
repair patients were 2.53 (±1.21), 2.32 (±1.04), 2.53
(±1.05) and 2.03 (±0.53) respectively. The mitral valve
repair patients had a significantly lower INR compared to
the mitral valve replacement patients (Figure 2).
The duration in which various INR levels were
controlled within the five ranges (less than 2, between 2 to
2.5 > 2.5 and 3.0, > 3.0 and 4.5 and greater than 4.5), were
37.80%, 25.36%, 14.81%, 17.85% and 4.1% respectively
(expressed as proportion to total study period). If we
consider the ranges of INR 3.0 to 4.5 as the acceptable
level of anticoagulation for mechanical valves, then for
only 17.85% of the study period was an adequate level of
anticoagulation maintained. The lone mitral valve repair
patient is excluded from this analysis.
The prosthetic heart valves used at the KNH over the
years have been of varying vintage. Most of the mechanical
valves implanted(65.2%) were of the first generation
variety. However, the second - generation mechanical
valves in this series were only used between May and June
1998 (Sorin bileaflet and Medtronic Hall valves). The
total follow up for the second generation valves was only
9,526 patient days (8.2%), out of the total follow up
period. In view of the very low follow up rate of those
valves, all the valves in this study have been considered to
be of the first generation.
Forty nine patients (48.0%) of the valve patients were
able to maintain an adequate INR(3.0 – 4.5) for only 10%
or less of the follow up time. While at the other extreme
only seven patients or 6.9% of the patients were able to
maintain an adequate INR control for 50% or more of the
follow up time (Figure 3).
DISCUSSION
As a consequence of the high drop out rate to clinic
follow up of post-heart valve surgery patients at the
Kenyatta National Hospital(10), the immediate question
that comes to mind is how effective is anticoagulation
control in this group of patients who do not seem to be
able to attend follow up reliably.
There has been no universally recommended period
for the interval of follow up in-between clinic visits for
patients on anticoagulation, and the cardiac unit of the
KNH recommends six to eight weeks for patients whose
INR is well controlled. For those out of control, more
frequent appointments are given, especially for those
over anticoagulated. It is important when deciding on a
suitable duration between clinic visits to strike a balance
between fine tuning of anticoagulation control and making
economical usage of the anticoagulation clinic both in
terms of cost and resources(8).
For this study the average duration between clinic
visits of 59 days (six visits a year) fell outside our
recommended range (with a wide standard deviation). In
addition to the relatively high drop-out rate during follow
up, the continuing patients only attended follow up six
times a year on average.
In an effort to maintain fine-tuning of INR, two
months may be too long an interval between clinic visits.
This situation is however understandable in our set up as
the economic realities make more frequent visits difficult
for the vast majority of our patients. The difficulty here
is both a problem of meeting the travelling expenses to
Nairobi in addition to the clinic consultation and
laboratory fees thereafter. Some patients do in fact request
long clinic intervals for this very season. Similar problems
have been noted in a similar population of patients from
South Africa(11). The setting up of anticoagulation units
outside Nairobi in the various provincial centres may
help as a part solution to this aspect of the problem. Other
factors often quoted for poor attendance in addition to
finances include those patients not aware of the
importance of regular follow up and those who, due to
feeling better after surgery see no need to attend clinics
on a regular basis(11).
There are probably a small number who do opt to
seek private follow up outside the hospital. Unfortunately
we have no records of this number but the author is sure
that in view of the socio-economic group of our patients
this number is no doubt very small. In fact a significant
number of patients who have their surgery in the private
setting often eventually opt for follow up at the KNH.
The majority of patients who attended follow up
regularly filled in their follow up details on their follow
up booklet diligently. This booklet is issued to all patients
on warfarin upon discharge and may have resulted in the
high (96.4% and 73.9%) retrieval rates for the INR level
and prescribed warfarin dosage respectively. The average
dose of warfarin prescribed (6.81mg) was slightly less
than that noted for a young age group by Routledge and
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co-workers(12). They also demonstrated that warfarin
dosage fell with increase in age to about 50% in the
elderly.
Nearly all the patients took less than 10mg daily to
maintain their INR. However three patients within the
study were on well over 10mg of warfarin with INR
values persistently below 2.0. In addition to warfarin
they were prescribed antiplatelet agents. Although anti-
platelets may help in first generation valves, controversy
still exists on the long-term use of antiplatelet agents
with the modern valves(11,12).
On a background of a significant level of under
anticoagulation (37.8%), the average change in dosage
of warfarin of three times in two years (or three times
during twelve clinic visits), gives the impression of
being an inadequate frequency and probably changes
will need to be made more often. In view of a 73.9% data
collection rate of warfarin dosages, there is possibility of
underestimation of the true number of changes. The
irregular patient attendances may also have significantly
influenced this result. More regular and frequent clinic
visits by the patients would probably give a more realistic
picture.
There have been various recommendations of the
optimal INR level for mechanical valves in the past.
Initially the range 3.0 – 4.5 for mechanical valves was
proposed. Unfortunately these figures were based on
population from the western world with differences to
ours both in age and primary pathology. These figures
were also derived from patients with a group of valve
types of the first generation, which are associated with a
thromboembolic rate twice that of second-generation
prosthesis(14). It is generally accepted following
recommendations of various individuals and
organisations that ideal INR for first generation
mechanical valves is of 3.0 – 4.5 while for second-
generation valves it is between 2.5 to 3.5(13,14). Butchart
introduced the concept of prosthesis specific
anticoagulation whereby the level of anticoagulation is
tailored to the specific prosthesis and individual patient(3).
Based on this concept, levels as low as 2.5 are used for
Medtronic Hall valves in the isolated aortic position and
3.0 in the isolated mitral position(7). This gives a relatively
good protection against thromboembolic episodes as
well as avoiding the dangers of anticoagulant-induced
bleeding. As a result of the wide variation of valves used
in this hospital over the years, all valves in this study
have been analysed as first generation valves. For this
study in the absences of a local recommendation of
ranges for INR, the recommendations of the British
Society of Haematology have been adopted.
Based on these figures, for only 17.9% of the follow
up time did our patients on average maintain adequate
INR levels. While at the same time for 37.8% of the
follow up time our patients were under anticoagulated,
(INR less than 2). Only a very poor 6.9% of our patients
were able to maintain an adequate level of INR control
for 50% or more of the follow up time. This finding is not
unexpected in view of poor long-term clinic follow up
rates in this hospital combined with the relatively long
inter-clinic visit interval.
In comparison, a similar figure demonstrating
inadequate maintenance of anticoagulation during follow
up of 12% was found in a comparable South African
population of heart patients(11). This figure, like ours, is
in sharp contrast to the best of centres with motivated
patients who report adequate long-term anticoagulation
rates up to 55 – 65%(15) of the follow up time.
“Adequate” anticoagulation by laboratory methods
only may not necessarily translate into clinical outcome
(thromboembolic phenomena, bleeding problems and
mortality) which are actually the main objectives of any
anticoagulation programme. A further study relating level
of anitcoagulation and follow up for morbidity and mortality
outcomes will be very useful in our set-up. There are a very
small number of patients who self regulate their
anticoagulation in our study group. One such patient in
this group being a medical staff member in this very
hospital. Patient regulated anticoagulation is used in some
centres with varying results(11) though in this hospital
with our patient population the author doubts whether we
are ready for this, and would not recommend it with the
exception of patients like the one mentioned with a medical
background.
In addition to better patient follow up, therapeutic
quality assessment is urgently needed in our clinic to
improve the anticoagulation control. It has been found in
many other centers, as in this study, that the main
problem with anticoagulation is under anticoagulation.
A clear lack of understanding of the management of INR
by junior staff was identified as a significant factor
contributing towards this. Unfortunately for a long time
in our clinic the role of reviewing INR follow up has been
left totally to them while the consultants reviewed the
new cases. This observation has been noted in other
hospitals as well, where junior staff tend to lean too much
on the side of caution(11).
Apart from the patient-related factors affecting
anticoagulation there are factors dependent on the
hospital. These include the various hospital service
charges, which can sometimes be a major problem in this
part of the world. Concurrent prescription of other
medications to the patient is a potential problem
underscoring that prescribing habits of physicians is
important(11). A change in the brand of warfarin issued
by the pharmarcy is a common complaint by patients
who note a sudden change in INR with the same dosage
of warfarin. This is a newly emerging problem as the
hospital moves more and more towards cheaper brands
of drugs (and sometimes poorer quality), in order to meet
its financial obligations.
In an effort to reduce errors arising as a result of
physician factors as well as to reduce the mundane
routine jobs in the clinic, computer aided anticoagulation
has been used in some centres with good results
indeed(16,11).
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This is a factor which we at a hospital like ours
should not rule out as the capital outlay is well within the
budgetary constraints of the hospital and would go a long
way in relieving doctors from the routine job of regulating
patient INR values. INR control can then be left to the
nursing staff and the doctors only concentrate on those
patients requiring special attention relating to their control.
Such low labour intensive techniques with greater patient
safely and accuracy have a lot of merit. Good results of
INR control of 63% or more during follow up time have
been achieved using this method(16).
In conclusion, the INR range of anticoagulation at the
KNH mostly fall in the “under anticoagulated range”.
Further research relating this to morbidity and mortality in
KNH is needed and appropriate measures taken. Areas to
be considered are patient’s attendance, staffing as well as
the acquisition of equipment to reduce workload and at the
same time increase the efficiency of services rendered.
Improvement should be directed not only towards attaining
better patient attendance of the clinic but also to educate
patients on the importance of adequate control. A formal
audit process to regularly evaluate progress and assess the
subsequent improvement, if any, will also have to be put
in place.
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